Memphasys Ltd Overview
Memphasys is a micro-cap Australian reproductive-biotechnology company. After almost two decades of separation-science R&D, it has narrowed its focus to a single commercial asset: the patented Felix™ System. Felix is a benchtop console with a single-use cartridge. It uses electrophoresis and size-exclusion membranes to isolate viable sperm in about six to seven minutes, without the centrifugation used in conventional density-gradient and swim-up preparation. The business model is a classic razor/razor-blade model. Consoles are placed in IVF laboratories, and every procedure uses a cartridge, at a company-targeted price of A$80–150. After CE Mark (Dec 2025), TGA (Feb 2026), MHRA, Vietnamese, Thai and Turkish registrations, Memphasys has signed 11 public commercial agreements covering 31+ countries. These carry A$4.2m+ in announced multi-year contracted minimums, anchored by an exclusive national agreement with Monash IVF Group. Revenue is still very small (A$274k in FY2026). The balance sheet is fragile, with a going-concern material uncertainty, so Memphasys is best characterised as an early commercial-stage, single-product medtech that is highly dependent on external funding.
Company's own description (paraphrased from the FY2026 Annual Report)
The FY2026 Directors' Report describes Memphasys as an Australian reproductive biotechnology company focused on commercialising its patented Felix™ System for assisted reproduction. During FY2026 its stated activities were: rolling out Felix through contracted distribution and direct sales; progressing regulatory approvals; scaling manufacturing while lowering cartridge cost to expand margins; and enforcing a disciplined cost structure. The report states that Felix is the company's sole commercial priority. RoXsta™ and other complementary fertility diagnostics are kept as longer-term pipeline options. Note 1 of the financial statements keeps a broader legacy description: development and manufacture of cell and protein separation devices and consumables for healthcare, veterinary and biotechnology markets.
Independent characterisation
Memphasys is a pre-scale, single-product medical-device company in the IVF laboratory consumables niche. It has three defining features:
-
Technology. Felix replaces the two incumbent sperm-preparation methods, density gradient centrifugation (DGC) and swim-up (SU). These methods have changed little in roughly 40 years. They take about an hour and are linked to oxidative stress and sperm DNA damage. Felix's differentiation rests on speed (about 6–7 minutes), standardisation (it is automated, so results depend less on the operator), and gentleness (no centrifugation).
-
Revenue model. Revenue comes from (a) console sales or placements, which are paid consoles in some deals, for example "200 cartridges + 6 paid consoles" in Thailand, and (b) recurring single-use cartridges, one per procedure. Management targets A$80–150 per cartridge and "60%+ gross margin potential at target COGS" (Sep 2026 presentation). FY2026 direct costs roughly equalled revenue (A$273.5k vs A$273.8k), so gross margin is currently close to zero.
-
Go-to-market. Two channels: (i) direct sales to IVF groups (Monash IVF in Australia; UK clinics; CFA Italia), and (ii) exclusive in-country distributors with minimum purchase obligations (ITL for MENA and Turkey; TMSC in Vietnam; IVF Envimed in Thailand; TK Biotech in Poland; NOVIVITAE in the Nordics; INVIDO LAB in the Czech Republic, Slovakia and one further market; Andrology Center Coimbatore / Andro Diagnostics in India; Vitrolife subsidiaries in Japan, Canada and New Zealand).
Revenue mix
| Revenue type | FY2026 (AUD) | Share of revenue | Source |
|---|---|---|---|
| Sale of Felix™ System (consoles and cartridges, recognised at a point in time) | 273,793 | 100% | FY2026 AR Note 5 |
| Services / subscription / licensing | 0 | 0% | FY2026 AR Note 5 |
| Memo: grant income (R&D Tax Incentive), not revenue | 384,175 | — | FY2026 AR Note 5 |
| Memo: other income (gain on disposal, interest, misc.) | 48,977 | — | FY2026 AR Note 5 |
The console/cartridge split is not publicly disclosed. Management says that recurring cartridge revenue is the strategic priority ("sole focus on annual recurring revenue (cartridge model)", April 2026 investor presentation).
Value-chain position
R&D: Conducted largely in partnership with the University of Newcastle (NSW) under Laureate Professor John Aitken (Scientific Director). Additional R&D was paused in FY2026.
Manufacturing: Outsourced to third-party manufacturers (FY2024 AR). The names of the contract manufacturers are not publicly disclosed. A cloud-based inventory and operations platform was implemented in the June 2026 quarter.
Regulatory and quality: Held in-house. The CE Mark under EU MDR is the regulatory "passport" used for reliance pathways in Australia, the UK, Qatar, India and elsewhere.
Distribution: Mixed direct and distributor model (see 2.2).
End user: IVF laboratory embryologists in fertility clinics.
Customer types and end-markets
| Customer type | Examples (disclosed) | End-market |
|---|---|---|
| Large corporate IVF networks | Monash IVF Group (22 Australian clinics); CFA Italia (Naples) | Human ART: IVF/ICSI |
| Public / state hospital IVF units | Hamad Medical Corporation (Qatar's largest IVF institution) | Human ART |
| Independent private fertility clinics | Four UK IVF groups in commercial evaluation; Japanese KOL clinics (Kobe, Reproduction Clinic Osaka, Kiba Park) | Human ART |
| Specialist IVF distributors | ITL (MENA/Turkey), TMSC (Vietnam), IVF Envimed (Thailand), TK Biotech (Poland), NOVIVITAE (Nordics), INVIDO LAB (Central Europe), Vitrolife subsidiaries (Japan, Canada, NZ) | Human ART |
| Animal breeding (pipeline, on hold) | Klean Gene Pty Ltd (adviser) | Livestock reproduction |
Strategy
Stated strategy (paraphrased themes from the FY2026 AR, Mar 2026 quarterly and Sep 2026 presentation)
-
Pure-play Felix focus. The 2025 AGM announced a deliberate repositioning towards commercialising Felix only. RoXsta, AI-Port and media were placed on hold.
-
Contracted, recurring revenue. Prioritise agreements with minimum annual cartridge volumes. The model is console placement, then cartridge pull-through, then repeat orders. Management's suggested investor KPI chain is: active clinics, then cartridge utilisation, then repeat orders, then recognised revenue.
-
Regulatory leverage. Use the EU MDR CE Mark as the anchor for reliance or abridged pathways (TGA, MHRA, Qatar, India CDSCO, Vietnam, Thailand, Turkey).
-
Direct plus distributor ("go-direct") model. Sell directly to large IVF groups (Monash, CFA, HMC, UK groups). Use exclusive in-country partners with minimums elsewhere.
-
Margin expansion. Scale cartridge manufacturing and reduce COGS towards a 60%+ gross margin at A$80–150 per cartridge.
-
Cost discipline. Restructuring cut quarterly operating outflows by 71% between the Dec 2025 and Jun 2026 quarters. Target burn of about A$250k a month.
Initiatives announced in the last 24 months
| Date | Initiative | Detail | Status |
|---|---|---|---|
| Sep 2025 | ITL MENA/Turkey partnership | 5-year exclusive; 15+ countries; about 353 clinics; about 140k cycles a year | Active |
| Oct–Dec 2025 | Recapitalisation | A$772.5k placement (Oct); rights issue and shortfall (Nov); A$579k placement (Dec); shares in lieu of fees and services | Completed |
| Nov 2025 | Pure-play repositioning | AGM strategy reset | Implemented |
| Dec 2025 | "Match-ready" pre-CE-Mark clinic programme | Pre-deployments, including a full-day Felix deployment at HMC in Doha; ESHRE/ASPIRE KOL engagement | Completed |
| H1 FY2026 | Operating restructure | Realigned structure; lower annualised costs; capital moved to manufacturing and sales | Completed |
| Feb 2026 | Regulatory acceleration | TGA lodgement leading to approval within weeks; MHRA registration process | Completed |
| Q4 FY2026 | Cloud inventory and operations platform | Demand forecasting, manufacturing planning, lead tracking | Implemented |
| Jun 2026 | Monash IVF national rollout | 12-month exclusive; 22 clinics after 3-month pilot | In progress |
| Jun 2026 | Manufacturing and inventory build | Funded mainly by the A$1.2m placement | In progress |
| Jun–Sep 2026 | Southeast Asia and wider Europe distributor network | Vietnam, Thailand, Poland, Nordics, Central Europe | Activating |
| Sep 2026 | European commercial team | "Newly established" to support distributors | Early |
| ESG / sustainability | None announced | — | — |
Targets and guidance
| Target | Value | Outcome |
|---|---|---|
| 2026 contracted sales goal | A$2.0m | Exceeded: about A$3.0m by Jul 2026; A$4.2m+ announced minimums by Sep 2026 |
| TGA approval | By Apr 2026 | Achieved Feb 2026 |
| Average monthly cash burn | About A$250k after the Dec 2025 quarter | Jun 2026 quarter about A$140k a month (A$422k), helped by payment timing |
| Gross margin at target COGS | 60%+ | Not yet achieved (about 0.1% in FY2026) |
| Sep 2026 quarter sales | Expected to be "significantly higher again" than Jun quarter | Report due mid/late Oct 2026 |
| Medium-term revenue or EBITDA targets | — | — |
Products & Services
Felix™ System (commercial; the only revenue-generating product)
| Attribute | Detail | Source |
|---|---|---|
| Description | Automated benchtop sperm-separation device for human ART (IVF/ICSI). Uses electrophoresis to drive charged, mature sperm through size-exclusion polymeric membranes, isolating viable cells without centrifugation | Company "About" text, 2026 releases |
| Components | (1) Felix console (capital item); (2) single-use Felix cartridge (consumable, one per procedure); (3) proprietary membranes, including biocompatible PVA polymeric membranes (AU patent 2017254772, granted 14 Sep 2023) | FY2024 Appendix 4E; Sep 2026 presentation |
| Processing time | About 6 minutes (Sep 2026 presentation); about 7 minutes (Osaka study); incumbent methods take about 1 hour | Sep 2026 presentation; FY2024 Appendix 4E |
| Pivotal clinical evidence | Registered, multi-centre, blinded, randomised sibling-oocyte trial across 10 Monash IVF centres in 103 couples. Primary endpoint, embryo utilisation rate: Felix 58.8% vs DGC 49.1% (p=0.022). Non-inferior to swim-up. 100% of clinicians preferred Felix to DGC. Results announced 24 Mar 2025 and presented at FSANZ on 9 Aug 2026 | Sep 2026 presentation; FSANZ release summary |
| Supporting evidence | Osaka (2024): blastocyst rate 58.4% vs 52.9%; good-quality blastocysts 35.7% vs 26.1%; embryo utilisation 58.0% vs 54.3% vs DGC+SU. Coimbatore (2023): 33 couples, 40 frozen transfers, 47.5% clinical pregnancy rate, 27.5% live-birth rate in a high-DNA-fragmentation cohort | FY2024 Appendix 4E |
| Regulatory status | CE Mark under EU MDR (Dec 2025); TGA/ARTG (Feb 2026); UK MHRA registration (2026); Vietnam registration (Aug 2026); Turkey ÜTS registration (Aug/Sep 2026); Thai FDA approval (by Sep 2026). Japan, Canada and NZ were treated as early-access markets with no pre-sale clearance required. India CDSCO pending. Company counts 6 regulatory clearances/registrations | Releases Dec 2025–Sep 2026; Sep 2026 presentation |
| Target customer | IVF laboratories: corporate networks, hospital units, independent clinics | — |
| Launch / latest version | Commercial sales in Japan from 2022–23. The "post-launch enhancement" version is capitalised as a separate intangible (A$1.28m net book value at 30 Jun 2026) | FY2026 AR Note 18 |
| Pricing model | Console sale or placement plus per-procedure cartridge. Company target A$80–150 per cartridge. Implied contract pricing: CFA Italia initial order 500 cartridges for A$62,500 (A$125 each); ITL about A$390k minimum for an initial 6,000-cartridge 5-year minimum (about A$65 each, distributor price, derived) | Sep 2026 presentation; ASX 22 Dec 2025; Jun 2026 quarterly |
| Target economics | "60%+" gross margin potential at target COGS. FY2026 actual gross margin about 0.1% (derived: revenue A$273,793 less direct costs A$273,488) | Sep 2026 presentation; FY2026 AR |
| Addressable market (company estimate) | About A$630m for Felix (FY2024 AR, citing Allied Market Research) | FY2024 Appendix 4E |
| IP | 14+ granted patents in the US and Australia | Sep 2026 presentation |
| Flagship accounts | Monash IVF Group (AU); Hamad Medical Corporation (Qatar), which has ordered a second console; CFA Italia; Japanese KOL clinics | — |
RoXsta™ (Rapid Oxidative Stress Assay), pipeline, scaled back
| Attribute | Detail |
|---|---|
| Description | Point-of-care in-vitro diagnostic with single-use cartridges. A five-minute test of antioxidant capacity in semen, blood, follicular fluid or urine, used as a proxy for oxidative stress |
| Applications | Male infertility, pre-eclampsia/placental failure research, livestock reproduction (bovine), and potentially sports medicine and food safety |
| Development | Co-developed with the University of Newcastle. An external product-development firm was contracted for the next iteration (FY2024). Small cartridge batch planned for early FY2025 |
| IP | AU provisional application 2023904171, "Methods and devices for measuring antioxidant levels in biological samples," filed 21 Dec 2023 |
| Spend | A$989,363 of research-phase spend in FY2024 (FY2023: A$646,791) |
| Status | Scaled back in FY2026 in favour of Felix and kept as a longer-term pipeline option (FY2026 AR) |
| Pricing / launch | Not publicly disclosed / not launched |
AI-Port (animal semen transport), pipeline, on hold
Ambient-temperature (22–25°C) livestock semen preservation for up to seven days, avoiding cryopreservation. Two field trials have been completed. Further work depends on funding and partners within the "Memphasys Animal Breeding Solutions" project. The related research line, "new long-life sperm storage media (animal)," absorbed A$663,723 in FY2024 (FY2023: A$528,893). Status: paused (FY2026 AR risk factor 2).
IVF and cryopreservation media, research stage, on hold
Novel cryoprotectant media were developed with the University of Newcastle. The company reported that adding vitamin C restored sperm vitality and DNA integrity after thawing, and that commercial cryoprotectant destroyed about 50% of antioxidant activity (published in Antioxidants, 2024). Not commercialised.
Discontinued and divested products
| Product | Status | Date | Source |
|---|---|---|---|
| Samson (rapid equine pregnancy prediction assay) | Discontinued (A$293,610 written to P&L in FY2023) | FY2023 | FY2024 Appendix 4E |
| SemPort (semen transport system) | Listed in historical pipeline; no current activity disclosed | — | Third-party profile |
| Precast electrophoresis gels (iGels, NuBlu, nUView) | Divested with NuSep Inc. to Dycent Biotech | Apr 2017 | MarketScreener |
| ProteoIQ proteomics software (BioInquire) | Legacy; status not disclosed | c.2012 | ASX release, Oct 2012 |
| PrIME Biologics (90% owned) | Legacy; status not disclosed | c.2012 | ASX release, Oct 2012 |
Financial Narrative
All figures are in AUD thousands (A$k) unless the row label says otherwise. FY2024 P&L figures follow the restated series in the FY2026 Remuneration Report unless marked "orig." Balance-sheet and cash-flow figures for FY2023–FY2024 come from the FY2024 Appendix 4E as originally reported. FY2025–FY2026 figures come from the audited FY2026 financial statements. FY2022 balance-sheet and cash-flow detail was not captured in the sources reviewed (blank cells).
Income statement
Sources: FY2026 AR P&L and Remuneration Report five-year table; FY2024 Appendix 4E for the FY2023–FY2024 line items. Discrepancies: (1) The FY2026 Appendix 4E gives "Underlying EBITDA" of -A$3,175k for FY2026 and -A$3,793k for FY2025. The Remuneration Report gives EBITDA of -A$3,094.9k and -A$3,801.5k. The difference reflects inclusion or exclusion of other income. (2) FY2024 EPS was originally -A$0.0019 and is -A$0.0023 restated.
Margins and growth (derived)
Revenue CAGR FY2022–FY2026 (4 years): 78.2% a year (derived: (273.8/27.1)^(1/4) − 1). The base is too small for this to be economically meaningful. Margins in the thousands of percent show that revenue is still immaterial relative to the cost base.
Balance sheet
Sources: FY2024 Appendix 4E; FY2026 AR. FY2022 cash and equity are taken from the FY2023 opening balances. Net debt = interest-bearing liabilities less cash (derived). Share-count anomaly: weighted-average shares are reported as 2,310.5m (FY2024) and 3,354.3m (FY2025), yet the closing count is 1,382.7m at 30 Jun 2024 and 1,983.6m at 30 Jun 2025. These figures do not reconcile in the filings reviewed and should be treated with caution.
Cash flow
Derived: FCF = OCF − capex (including capitalised development and cleanroom payments). Net borrowings combine third-party and related-party loan receipts less repayments.
Ratios (derived)
ROE uses average equity, with restated FY2024 equity where available. ROIC is not meaningful with negative NOPAT and is left blank. Net debt/EBITDA is negative because EBITDA is negative, which means the ratio cannot be interpreted conventionally. Cash conversion cycle: not meaningful. Derived FY2026 indicators: receivables of A$163k against revenue of A$274k (about 217 days of sales); trade payables rose from A$126k to A$1,381k, implying stretched supplier terms.
Trend commentary
Revenue inflection, from a near-zero base. Revenue was essentially nil for four years. It was A$27k in FY2022 and A$3.7k in FY2025, and came from Japanese early-access sales through Vitrolife. In FY2026 it reached A$273.8k, with 96% earned in the second half: 1H FY2026 A$12.4k, March quarter about A$112k, June quarter about A$150k (Jun 2026 quarterly). The driver was the regulatory unlock. CE Mark (Dec 2025) and TGA (Feb 2026) activated distributor minimums, with ITL ordering 1,800 cartridges, and led to initial orders from CFA Italia, UK trial clinics and Monash IVF. Management also disclosed "contracted FY26 sales of A$3m," later "A$4.2m+ minimum contracted sales publicly announced" (Sep 2026). These are multi-year minimum commitments, not recognised revenue, and investors should not treat them as an annual run-rate.
Gross margin has not yet emerged. FY2026 direct costs of A$273.5k matched revenue almost exactly. Possible reasons include early-volume manufacturing cost, console sales at or near cost, and inventory set-up. Management's 60%+ target therefore depends entirely on cutting cartridge COGS at scale. This is flagged as a key business risk ("Manufacturing costs," FY2026 AR risk 16).
Losses are narrowing because the cost base is shrinking, not because the business is scaling. Net loss fell 19% to A$4.10m. The drivers were lower R&D (down A$315k as RoXsta was scaled back), lower finance costs (down A$202k after third-party loans were repaid), and the absence of the FY2025 A$896k impairment. These savings were partly offset by much higher compliance, registry, accounting and legal costs (up A$448k to A$779k) and director expenses (up A$110k). Quarterly operating cash outflows fell 71%, from A$1.441m (Dec 2025 quarter) to A$831k (Mar 2026) and then A$422k (Jun 2026). Management guided to an average burn of about A$250k a month after the December quarter (1H FY2026 report).
The balance sheet depends on equity issuance and one lender. The company has raised A$3.4–4.0m of gross equity every year from FY2023 to FY2026, about A$14.8m in total. That broadly matches cumulative free-cash outflow. Shares on issue grew about 2.2x from 1,382.7m (Jun 2024) to 3,087.2m (Jun 2026), and 779m options are outstanding. The only interest-bearing debt is the A$4.24m (carrying value) Peters Investments convertible note. It is classified as current and has been extended repeatedly, most recently to 30 Jun 2027. Working capital is negative at -A$4.81m. Net assets of A$4.21m are less than the A$8.80m of Felix intangibles, so net tangible assets are negative (about -A$4.58m, derived). The auditor (BDO) included a material-uncertainty-related-to-going-concern paragraph for FY2026.
Intangibles are a valuation judgement. The Felix intangible (cost A$19.4m, less A$7.7m of R&D grants offset, less amortisation and impairment) is amortised over 20 years, which is long for a medical device. Its carrying value is supported by an impairment review that cites contracts and approvals rather than a disclosed discounted-cash-flow model.
Restatement note
The FY2026 Remuneration Report labels FY2024 as "Restated." It shows a FY2024 loss of A$5,371,322 against A$4,442,021 originally reported. The A$929,301 difference exactly equals the FY2024 grant income originally booked to P&L. Opening equity at 1 Jul 2024 was likewise reduced from A$6,837,755 to A$5,908,454 (a difference of A$929,301). The most likely explanation (an inference, not confirmed in the text reviewed) is that the R&D Tax Incentive was reclassified against capitalised development costs, consistent with the FY2026 policy note 3(i). Readers should use the restated FY2024 series for comparability.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products / services | Status |
|---|---|---|---|
Reproductive Technologies | Felix™ System (human sperm separation); Felix membranes; RoXsta™ (oxidative-stress assay); AI-Port (animal semen transport); IVF/cryopreservation media; legacy separation IP | Consoles; single-use cartridges; pipeline diagnostics | Felix is commercial. All other projects are paused or on hold |
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Segment revenue (AUD K) | 27.1 | 15.4 | 60.0 | 3.7 | 273.8 |
Segment revenue YoY growth (%) | — | -43.4 | 290.3 | -93.8 | 7,300.0 |
Segment pre-tax loss (AUD K) | -2,082.0 | -3,402.6 | -5,371.3 | -5,039.1 | -4,103.4 |
Segment EBIT (AUD K) | -2,249.9 | -2,992.5 | -4,970.1 | -4,467.8 | -3,719.6 |
Contribution to group revenue (%) | 100 | 100 | 100 | 100 | 100 |
Function Details
| Function | Lead (FY2026/27) | Notes |
|---|---|---|
Board / strategy | David Tasker (Chair) | No CEO since 31 Dec 2025 |
Commercialisation Committee | Marjan Mikel (Chair) | Paid strategic consultancy through Mikel Enterprises |
Clinical engagement & growth | A/Prof Hassan Bakos | Formerly Director of Operations |
Scientific | Laureate Prof John Aitken | Ceased to be KMP from 1 Jul 2026 |
ANZ key accounts | Dr Tony Poulton | Appointed in the Jun 2026 quarter for the Monash rollout |
European commercial team | "Newly established" (Sep 2026) | Head not named in the sources reviewed |
Finance / company secretarial | Stefan Ross (Co. Sec., Vistra) | Director of Finance Pablo Neyertz resigned 14 Nov 2025. Current CFO: not publicly disclosed |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD K) | 27.1 | 15.4 | 60.0 | 3.7 | 273.8 |
Direct costs (AUD K) | — | 6.2 | 58.4 | 39.3 | 273.5 |
Gross profit (AUD K) | — | 9.2 | 1.6 | -35.6 | 0.3 |
Grant income, R&D Tax Incentive (AUD K) | — | 588.0 | 929.3 | 523.2 | 384.2 |
R&D expense through P&L (AUD K) | — | 1,469.3 | 2,138.6 | 1,294.5 | 979.7 |
Employee benefits expense (AUD K) | — | 221.2 | 852.7 | 888.5 | 930.0 |
Compliance, audit, tax and legal (AUD K) | — | 263.3 | 332.0 | 330.5 | 778.6 |
Depreciation and amortisation (AUD K) | — | 619.4 | 717.0 | 666.3 | 593.0 |
Impairment of intangibles (AUD K) | — | 0 | 0 | 896.4 | 0 |
EBITDA (AUD K) | -2,126.7 | -2,379.7 | -4,257.7 | -3,801.5 | -3,094.9 |
Operating income / EBIT (AUD K) | -2,249.9 | -2,992.5 | -4,970.1 | -4,467.8 | -3,719.6 |
Finance costs (AUD K) | — | 428.2 | 417.1 | 585.4 | 383.8 |
Pre-tax income (AUD K) | -2,082.0 | -3,402.6 | -5,371.3 | -5,039.1 | -4,103.4 |
Income tax (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net income (AUD K) | -2,082.0 | -3,402.6 | -5,371.3 | -5,039.1 | -4,103.4 |
Net income as originally reported (AUD K) | -2,082.0 | -3,402.6 | -4,442.0 | -5,039.1 | -4,103.4 |
EPS basic (AUD) | -0.0027 | -0.0018 | -0.0023 | -0.0015 | -0.0016 |
EPS diluted (AUD) | -0.0027 | -0.0018 | -0.0023 | -0.0015 | -0.0016 |
Dividends per share (AUD) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | — | 60.0 | 2.7 | -961.9 | 0.1 |
EBITDA margin (%) | -7,834 | -15,482 | -7,096 | -102,743 | -1,130 |
Operating (EBIT) margin (%) | -8,288 | -19,469 | -8,284 | -120,751 | -1,359 |
Net margin (%) | -7,669 | -22,137 | -8,952 | -136,192 | -1,499 |
Revenue YoY growth (%) | — | -43.4 | 290.3 | -93.8 | 7,300.0 |
Balance Sheet and Share Count (millions)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and equivalents (AUD K) | 269.1 | 637.8 | 277.8 | 298.3 | 1,178.5 |
Inventories (AUD K) | — | 130.8 | 164.8 | 58.8 | 165.7 |
R&D Tax Incentive receivable (AUD K) | — | — | — | 900.9 | 384.2 |
Total current assets (AUD K) | — | 2,248.7 | 1,618.6 | 1,333.3 | 2,204.3 |
Intangible assets, Felix (AUD K) | — | 10,294.7 | 10,089.8 | 9,298.0 | 8,795.6 |
Goodwill (AUD K) | — | 0 | 0 | 0 | 0 |
Total assets (AUD K) | — | 14,667.8 | 12,430.1 | 11,211.8 | 11,235.9 |
Short-term interest-bearing debt (AUD K) | — | 4,469.4 | 4,363.2 | 4,866.5 | 4,244.1 |
Long-term interest-bearing debt (AUD K) | — | 0 | 0 | 0 | 0 |
Lease liabilities, total (AUD K) | — | 1,825.4 | 396.0 | 335.9 | 0 |
ATO / other statutory liabilities (AUD K) | — | 47.6 | 70.8 | 1,162.5 | 1,062.5 |
Total current liabilities (AUD K) | — | 5,567.3 | 5,254.1 | 6,591.5 | 7,019.0 |
Total liabilities (AUD K) | — | 7,283.2 | 5,592.4 | 6,870.1 | 7,023.2 |
Net debt excl. leases (AUD K) | — | 3,831.6 | 4,085.4 | 4,568.2 | 3,065.6 |
Total equity (AUD K) | 7,646.5 | 7,384.7 | 6,837.8 | 4,341.6 | 4,212.7 |
Total equity, FY2024 restated (AUD K) | — | — | 5,908.5 | — | — |
Working capital (AUD K) | — | -3,318.6 | -3,635.5 | -5,258.2 | -4,814.7 |
Issued capital (AUD K) | 50,340.9 | 53,417.8 | 57,280.3 | 60,613.3 | 64,511.2 |
Accumulated losses (AUD K) | -42,770.6 | -46,173.2 | -50,430.1 | -56,274.1 | -60,377.5 |
Shares on issue at year end (millions) | — | — | 1,382.7 | 1,983.6 | 3,087.2 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Receipts from customers (AUD K) | — | 15.4 | 60.0 | 3.7 | 118.1 |
Government grant receipts (AUD K) | — | 1,504.0 | 1,315.1 | 1,119.0 | 900.9 |
Operating cash flow (AUD K) | — | -1,406.7 | -3,231.4 | -2,401.3 | -2,490.5 |
Capex incl. capitalised development (AUD K) | — | 1,976.7 | 715.6 | 819.7 | 3.4 |
Free cash flow (AUD K) | — | -3,383.4 | -3,947.0 | -3,221.0 | -2,493.9 |
Equity issued, gross (AUD K) | — | 3,360.4 | 3,721.0 | 3,730.1 | 3,964.4 |
Net borrowings (AUD K) | — | 774.0 | 289.5 | -19.7 | -479.3 |
Net financing cash flow (AUD K) | — | 3,752.1 | 3,539.6 | 3,253.1 | 3,374.1 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
ROE (%) | -45.3 | -80.8 | -98.3 | -95.9 |
ROA (%) | — | -39.6 | -42.6 | -36.6 |
Current ratio (x) | 0.40 | 0.31 | 0.20 | 0.31 |
Debt / equity (x) | 0.61 | 0.64 | 1.12 | 1.01 |
Net debt / EBITDA (x) | -1.61 | -0.96 | -1.20 | -0.99 |
Interest coverage, EBIT / finance costs (x) | -7.0 | -11.9 | -7.6 | -9.7 |
Asset turnover (x) | — | 0.004 | 0.0003 | 0.024 |
Revenue by Region
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total revenue (AUD K) | 60.0 | 3.7 | 273.8 |
Revenue, Southeast Asia (AUD K) | — | — | 0 |
Revenue by Region (Quarterly)
| Metric | 1H FY2026 | Q3 FY2026 | Q4 FY2026 |
|---|---|---|---|
Revenue (AUD K) | 12.4 | 112.0 | 150.0 |
Region Overview
| Region | Status | Contracted minimum / volumes disclosed | Growth assessment |
|---|---|---|---|
MENA (Qatar, UAE, Iraq, Kuwait, plus 15+ countries) | Fastest early adopter. ITL orders of 1,800 cartridges (72% of the 2,500 annual minimum) within two quarters of CE Mark. HMC ordered a second console | About A$390k minimum over 5 years | Fastest-growing. Driven by CE-Mark reliance, distributor minimums and HMC reference |
Australia | Monash IVF 12-month exclusive national agreement; 2-site, 3-month rollout leading to 22 clinics | Terms confidential | High potential. Monash performed 12,085 stimulated cycles in 2025, about 21% of the national market |
Europe – Italy | CFA Italia 5-year agreement; initial 500-cartridge order; repeat orders | About A$925k minimum; 7,500 cartridges, front-loaded | Growing |
UK | Four IVF groups in paid commercial evaluation after MHRA registration | Not contracted | Early |
Europe – Poland | TK Biotech exclusive (5 Aug 2026); first minimum order expected in the Dec 2026 quarter | Not captured | Early |
Europe – Nordics (5 markets) | NOVIVITAE exclusive (1 Sep 2026) | €526,500 | Early |
Europe – Czech Republic, Slovakia and one further market | INVIDO LAB, 3-year exclusive (18 Sep 2026) | About A$674k (at €1 = A$1.62) | Early |
Turkey | ÜTS registration; first sale of 100 cartridges and 2 consoles from existing ITL stock (not incremental to Memphasys) | Within the ITL agreement | Early. About 75,000 ART cycles a year; 165 centres targeted |
Vietnam | Registered Aug 2026; 600-cartridge commercial order triggered (700 in total) | About A$530.2k over 2 years | Accelerating |
Thailand | Thai FDA approval activated the 3-year agreement; 200 cartridges and 6 paid consoles | About A$430.5k over 3 years | Accelerating |
India | Awaiting CDSCO approval, which was expected in the Sep 2026 quarter. | About A$98.8k in year 1, rising to about A$148k in year 2 | Pending |
Japan | Repeat use through Vitrolife Japan KK. Reimbursement hurdle limits the addressable market to the about 20% unreimbursed private segment | — | Stagnant/declining after FY2024. Revenue fell to A$3.7k in FY2025, pending trial data and reimbursement |
Canada / New Zealand | Vitrolife 5-year agreements (Jan 2024); training and evaluation only | — | Dormant |
“—” = not publicly disclosed.
Share Price and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at start of FY (AUD) | 0.064 | 0.040 | 0.014 | 0.007 | 0.004 |
Share price at end of FY (AUD) | 0.040 | 0.014 | 0.007 | 0.004 | 0.007 |
FY share price change (%) | -37.5 | -65.0 | -50.0 | -42.9 | 75.0 |
Basic EPS (AUD) | -0.0027 | -0.0018 | -0.0023 | -0.0015 | -0.0016 |
Share Price & Returns
| Horizon | Reference start price | Approximate change |
|---|---|---|
1-year (late Oct 2025, A$0.004 at 31 Oct 2025) | 0.004 | +38% |
3-year (30 Jun 2023 close as proxy) | 0.014 | -61% |
5-year (1 Jul 2021 as proxy) | 0.064 | -91% |
Valuation Snapshot
| Metric | Value | Basis |
|---|---|---|
Market capitalisation | About A$17.0m | 3,095.2m shares (incl. 8m to Chapter One) × A$0.0055 |
Enterprise value | About A$20.1m | Market cap + A$4.24m note − A$1.18m cash (30 Jun 2026). Excludes the A$1.06m ATO liability |
EV / Sales FY2026 | About 73x | EV / A$0.274m |
EV / contracted minimums | About 4.8x | EV / A$4.2m multi-year minimums (not annual) |
P/E | Not meaningful (loss-making) | — |
EV / EBITDA | Not meaningful (negative EBITDA) | — |
P/B | About 4.0x | A$17.0m / A$4.21m equity |
Price / tangible book | Not meaningful (negative NTA) | — |
Fully diluted shares (company) | About 5.62bn | Shares + options + note conversion at A$0.0024 (Sep 2026 presentation) |
Capital Markets
| Item | Status |
|---|---|
Sell-side coverage / consensus | None identified (not publicly disclosed) |
Dividend history and policy | No dividends paid; none recommended (FY2026). No dividend policy |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Share Price & Returns by Date
| Date | Type | Shares (m) | Price (AUD) | Proceeds (AUD K) |
|---|---|---|---|---|
1 Oct 2025 | Placement | 257.5 | 0.003 | 772.5 |
10 Nov 2025 | Rights issue shortfall | 180.5 | 0.003 | 541.4 |
11 Nov 2025 | Tranche 2 placement (incl. director) | 33.3 | 0.003 | 100.0 |
19 Dec 2025 | Shares in lieu of director fees | 6.6 | 0.003 | 19.8 |
30 Dec 2025 | Placement | 193.1 | 0.003 | 579.2 |
31 Dec 2025 | Shares for services | 26.0 | 0.003 | 78.0 |
16 Feb 2026 | Placement | 160.0 | 0.005 | 800.0 |
26 Jun 2026 | Placement | 240.0 | 0.005 | 1,200.0 |
Capital Instruments
| Instrument | Lender | Face / carrying (AUD K) | Rate | Maturity | Security | Conversion |
|---|---|---|---|---|---|---|
Convertible notes | Peters Investments Pty Ltd (13.19% holder as last disclosed) | 4,135.8 face; 4,244.1 carrying incl. accrued interest | 8% (interest and fees also accrue interest) | 30 Jun 2027 | Unsecured | A$0.0024 per share (Sep 2026 presentation) |
Third-party secured loan (R&D refund-backed) | Third party | 0 (repaid in FY2026; 638.3 at FY2025) | 15% | Repaid | R&D refund | — |
Metric | FY2027 | FY2028 | FY2029 | — | — | — |
Scheduled debt maturities (AUD K) | 4,244.1 | 0 | 0 | — | — | — |
Analyst Conclusions
Management guidance and outlook (Jun 2026 quarterly; FY2026 AR; Sep 2026 presentation)
-
September 2026 quarter sales expected to be "significantly higher again" than the June quarter (A$150k). Drivers: Monash rollout, Turkey, Vietnam and Thailand activations, ITL repeat orders, UK conversions.
-
Priorities: finish the Monash 2-site pilot and move to the 22-clinic national rollout; convert UK trials to contracts; secure Indian CDSCO approval; support Vietnam and Thailand launches; grow MENA and European utilisation; reduce COGS and expand margins.
-
Funding: cash runway of 2.8 quarters at 30 Jun 2026. Continued reliance on Lynx-supported placements. Options for the Peters note (repay, restructure or convert) to be considered before 30 Jun 2027.
-
Formal revenue or EBITDA guidance: not provided.
Consensus
No sell-side consensus exists. Analyst framework (derived, illustrative only): if all A$4.2m+ of announced minimums were delivered evenly over an average 3–4 year term, contracted revenue would be about A$1.1–1.4m a year. That is roughly 4–5x FY2026 revenue, before any Monash volumes, but still well below the annual cash cost base of about A$3–3.5m. Cash break-even needs either much higher utilisation (Monash national rollout plus Europe) or gross margins approaching the 60% target.
Bull case
-
Evidence plus approvals equals adoption. RCT-grade superiority over DGC (p=0.022), combined with CE, TGA, MHRA and Asian registrations, gives Felix a credible clinical and regulatory moat. The MENA ramp (1,800 cartridges in about two quarters) shows that distributor minimums can turn into orders quickly.
-
The Monash rollout is a step change. A move to 22 clinics and about 12,000 stimulated cycles a year would make Australia a reference market. Even 25% Felix penetration at A$100 per cartridge implies about A$0.3m a year from Monash alone, more than all FY2026 revenue (derived).
-
Operating leverage and optionality. Burn has fallen to about A$140–250k a month. Revenue growth from 11 agreements, a 60%+ gross-margin target, paused pipeline assets that could be partnered (RoXsta, AI-Port), and a A$17m market cap leave room for a re-rating or strategic acquisition by an IVF consumables major.
Bear case
-
Funding and dilution spiral. Negative working capital (-A$4.8m), negative NTA, a going-concern uncertainty and a A$4.2m note due Jun 2027. Further placements at 0.3–0.5¢ and note conversion (about 1.75bn shares) could dilute existing holders heavily and give Peters effective control.
-
Unit economics are unproven. Gross margin was about 0% in FY2026. Cartridges at A$80–150 compete with near-zero-cost gradient media and swim-up, with no reimbursement. Distributor price points of about A$65 implied under the ITL minimums leave little margin unless COGS falls sharply.
-
Governance and execution capacity. No CEO or CFO, a 3-person board with two related-party commercial relationships, dissolved committees, a FY2024 restatement and inconsistent share data. Managing 11 international partners with this structure carries high execution risk.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable | What to watch |
|---|---|---|
| Oct 2026 | Sep 2026 quarterly / Appendix 4C | Revenue vs A$150k; cash receipts (Jun-quarter receivables); burn; cash balance |
| Q4 CY2026 | Monash pilot completion and national rollout | Formal trigger of the 12-month term; number of active clinics |
| Q4 CY2026 | India CDSCO approval | Activation of the Andro Diagnostics minimums |
| 25 Nov 2026 | AGM | Board renewal; capital approvals; CEO appointment |
| 5 Nov 2026 | Expiry of about 470m options at 1.1¢ | Overhang falls unless the share price rises above 1.1¢ |
| Dec 2026 quarter | First Poland minimum order; Nordic and INVIDO orders | Conversion of European distributors |
| H1 CY2027 | UK contract conversions | Recurring UK cartridge orders |
| By 30 Jun 2027 | Peters Investments note resolution | Repayment, extension, restructure or conversion |
| Ongoing | Gross margin and COGS | Progress towards 60%+ |
| Ongoing | Peer-reviewed publication of the Monash pivotal trial | Independent validation for KOLs |
Analyst verdict
Memphasys is at a real but fragile inflection point. After nearly 20 years as a separation-science company that never generated meaningful revenue, it has done three hard things in 18 months. It produced randomised multi-centre evidence that Felix beats density-gradient centrifugation on embryo utilisation. It secured a CE Mark under the demanding EU MDR, followed quickly by TGA, MHRA and several Asian and Turkish registrations. And it signed 11 commercial agreements with more than A$4.2m of announced minimums, including an exclusive national arrangement with Monash IVF. FY2026 revenue rose from A$3.7k to A$274k, with record June-quarter revenue of A$150k. These are not trivial achievements for a company valued at about A$17m.
The financial position, however, leaves almost no room for error. Gross margin was effectively zero in FY2026. Working capital is negative A$4.8m, net tangible assets are negative, and the auditor flagged a material going-concern uncertainty. A A$4.2m convertible note, convertible at a fraction of a cent, matures in June 2027. The company has no CEO or CFO. Its three-person board includes two directors with paid commercial relationships, and its audit committee has been dissolved. The share count has more than doubled in two years, and more dilution is likely.
On balance, Memphasys is a high-risk, binary, speculative situation. The commercial thesis is now evidence-based and its contractual footprint is unusually broad for its size. Equity value, however, depends on three things happening within about 12 months: the Monash rollout reaching national scale, cartridge COGS falling enough to produce the targeted gross margins, and the Peters note being resolved without a disorderly change of control.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Education | Holdings (30 Jun 2026) |
|---|---|---|---|---|---|
David Tasker | Non-Executive Chair (described as independent) | 19 May 2026 | MD and co-founder of Chapter One Advisors (Perth IR/media firm); 13+ years as National Director IR at PPR; IR adviser to Memphasys for 7+ years | BCom (Marketing & Management), Murdoch University | 51,102,070 shares (indirect); 15,666,666 options |
Marjan Mikel | Non-Executive Director; Chair, Commercialisation Committee | 19 Jun 2025 | CEO and MD of Vitasora Health (ASX: VHL); founding MD of Healthy Sleep Solutions (ResMed cornerstone, sold to Air Liquide); MSD, Pharmacia, IMS Health | MCom; BSc (Hons); Grad Dip Ed; MAICD | 15,838,792 shares; 26,666,667 options |
Mathew Watkins | Independent Non-Executive Director | 20 Oct 2025 | Chartered Accountant; Australia Market Lead at Vistra; company secretary to several ASX entities | BBus; CA | Nil |
Board of Directors — Dr Lindley Edwards
| Name | Role | Departure | Notes |
|---|---|---|---|
Dr Lindley Edwards | Non-Executive Chair | Resigned 18 May 2026 | CEO, AFG Venture Group. AFG was paid A$80,673 for advisory services |
Dr David Ali | Executive Director and CEO | Left board 20 Oct 2025; ceased as CEO 31 Dec 2025 | BSc, PhD (Macquarie); 40+ years in reproductive pharma/devices |
Paul Wright | Independent NED | Resigned 10 Sep 2025 | NED of Hydrix Ltd |
Michael Atkins | Independent NED | Resigned 25 Jul 2025 | NED of SRG Global |
Board of Directors — A/Prof Hassan Bakos
| Name | Title | Notes |
|---|---|---|
A/Prof Hassan Bakos | Director – Clinical Engagement & Growth (formerly Director of Operations) | 20+ years in ART leadership. Base salary A$250,000 plus super; STI up to 20%, LTI up to 25% |
Laureate Prof John Aitken | Scientific Director | Architect of the Felix science. Ceased to be KMP from 1 Jul 2026 |
Dr Tony Poulton | Key Account Manager, ANZ | 20+ years at Cardinal Health and Covidien. Leads the Monash rollout |
Stefan Ross | Company Secretary (from 8 Oct 2025) | Vistra; replaced Andrew Metcalfe |
CEO / CFO | Vacant / not publicly disclosed | No CEO since 31 Dec 2025. Director of Finance Pablo Neyertz resigned 14 Nov 2025 |
Directors' Remuneration
| Name | Cash salary and fees | STI | Super | Long service leave | Options (SBP) | Total |
|---|---|---|---|---|---|---|
Lindley Edwards | 82,212 | 0 | 9,865 | 0 | 0 | 92,077 |
Paul Wright | 6,676 | 0 | 0 | 0 | 0 | 6,676 |
Michael Atkins | 2,214 | 0 | 0 | 0 | 0 | 2,214 |
Marjan Mikel | 168,530 | 0 | 0 | 0 | 28,005 | 196,535 |
Mathew Watkins | 34,949 | 0 | 0 | 0 | 0 | 34,949 |
David Tasker | 9,375 | 0 | 0 | 0 | 35,064 | 44,439 |
David Ali | 288,531 | 0 | 29,700 | 0 | 0 | 318,231 |
Pablo Neyertz (incl. A$40,384 termination) | 168,420 | 0 | 11,550 | 0 | 0 | 179,970 |
Hassan Bakos | 250,000 | 0 | 30,000 | 5,813 | 13,710 | 299,523 |
Total KMP | 1,010,907 | 0 | 81,115 | 5,813 | 76,779 | 1,174,614 |
Major Shareholders
| Holder | Shares | % (as last disclosed) | Indicative % of 3,087.2m shares (derived) | Source |
|---|---|---|---|---|
Peters Investments Pty Ltd (also convertible noteholder) | 261,564,791 | 13.19 | 8.47 | Substantial holder data (InvestSMART) |
Andrew Goodall | — | Described as second-largest shareholder (Aug 2024) | — | FY2024 Appendix 4E |
Alison Coutts (former MD) | 88,707,336 | 6.49 (Nov 2023) | — | MarketScreener |
David Tasker (Chair) | 51,102,070 | — | 1.66 | FY2026 AR |
Marjan Mikel | 15,838,792 | — | 0.51 | FY2026 AR |
Lindley Edwards (former) | 5,848,840 | — | 0.19 | FY2026 AR |
“—” = not publicly disclosed.
Competitive Landscape
Key Competitors
| # | Competitor / product | Company | Approach | Positioning vs Felix |
|---|---|---|---|---|
| 1 | Density gradient media (e.g., SpermGrad) | Vitrolife Group (Sweden) | DGC (centrifugation) | The incumbent standard. Very low cost per sample; globally entrenched. Ironically, Vitrolife is also Memphasys' distributor in Japan, Canada and NZ |
| 2 | Isolate and sperm-washing media | FUJIFILM Irvine Scientific | DGC media | Incumbent; broad IVF media portfolio |
| 3 | PureSperm | Nidacon International | DGC media | Incumbent |
| 4 | ORIGIO gradient media; PICSI hyaluronan-binding dish | CooperSurgical (Cooper Companies) | DGC; hyaluronan-binding selection | Global IVF consumables leader with bundled portfolio |
| 5 | ZyMōt microfluidic sperm separation device | ZyMōt Fertility (DxNow) | Microfluidic, centrifuge-free | Closest functional substitute. Centrifuge-free, low DNA fragmentation, no capital console |
| 6 | Fertile chip (microfluidic) | Koek Biotechnology | Microfluidic | Low-cost chip; direct alternative |
| 7 | LensHooke sperm separation device | Bonraybio | Microfluidic/filtration | Lower-cost alternative |
| 8 | MACS ART Annexin V | Miltenyi Biotec | Magnetic-activated cell sorting (removes apoptotic sperm) | Adjunct for high-DNA-fragmentation cases |
| 9 | Swim-up (method, no vendor) | — | Migration | Free method; Felix trial showed non-inferiority |
| 10 | IMSI / high-magnification selection | Various microscope OEMs | Morphological selection | Adjacent, labour-intensive |
| 11 | Lab automation and equipment players | Hamilton Thorne and others | Analysis and lab equipment | Potential entrants or partners in automation |
Peer Comparison FY2026
| Metric | Memphasys (FY2026) | ZyMōt Fertility |
|---|---|---|
Revenue | A$0.27m | Private; not disclosed |
Revenue growth | +7,300% (from A$3.7k) | — |
Gross margin | About 0.1% | — |
EBITDA margin | About -1,130% | — |
R&D intensity (total R&D / revenue) | About 358% | — |
Regulatory | CE (MDR), TGA, MHRA, VN, TH, TR | FDA-cleared; CE |
“—” = not publicly disclosed.
Recent Developments
The company states it is "free of any litigation claims" (FY2026 AR).



